Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Published In:
- Frontiers in pharmacology, 9, 576 (2018)
- Authors:
- Shi, Fang-Hong, Li, Hao(4), Cui, Min, Zhang, Zai-Li, Gu, Zhi-Chun, Liu, Xiao-Yan
- Database ID:
- RPEP-03899
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-03899APA
Shi, Fang-Hong; Li, Hao; Cui, Min; Zhang, Zai-Li; Gu, Zhi-Chun; Liu, Xiao-Yan. (2018). Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. Frontiers in pharmacology, 9, 576. https://doi.org/10.3389/fphar.2018.00576
MLA
Shi, Fang-Hong, et al. "Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.." Frontiers in pharmacology, 2018. https://doi.org/10.3389/fphar.2018.00576
RethinkPeptides
RethinkPeptides Research Database. "Efficacy and Safety of Once-Weekly Semaglutide for the Treat..." RPEP-03899. Retrieved from https://rethinkpeptides.com/research/shi-2018-efficacy-and-safety-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.